Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination
- 30 September 2011
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 47 (13), 1955-1961
- https://doi.org/10.1016/j.ejca.2011.04.019
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinomaAnnals of Oncology, 2011
- Blocking Angiotensin II Type 1 Receptor Triggers Apoptotic Cell Death in Human Pancreatic Cancer CellsPancreas, 2010
- Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall SurvivalJournal of Clinical Oncology, 2010
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter StudyJournal of Clinical Oncology, 2009
- The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancerGut, 2009
- Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapyZeitschrift für Krebsforschung und Klinische Onkologie, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinomaCancer, 2008
- The renin-angiotensin system and malignancyCarcinogenesis: Integrative Cancer Research, 2008
- Novel approaches in the therapy of metastatic renal cell carcinomaWorld Journal of Urology, 2005